Fig. 1
From: Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
The inhibitory effect of INC280 and MetMab in cancer cell proliferation and the MET signaling pathway. a, b HGF-autocrine cancer cells JHH5 and U87 (a) and MET-amplified cancer cells MKN45 and MHCC97H (b) were treated with either INC280 or MetMab for 72 h at various concentrations as indicated. Cell survival was measured using a Cell-titer Glo assay. Survival rate = Luminescence signal intensity of treated samples at indicated concentration/untreated samples. Triplicates were used for each concentration. Vertical bar refers to standard deviation. c, d Western blots of MET and downstream signaling pathway proteins and the inhibition by INC280 or MetMab in the presence or absence of HGF (100 ng/ml) stimulation in either HGF-autocrine cancer cells (c) or MET-amplified cancer cells (d). Note that MetMab only inhibited the MET signaling pathway in HGF-autocrine JHH5 and U87 cells regardless of HGF stimulation